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Summary 
Antigen presentation by host dendritic  cells  (DC)  is critical for the initiation of adaptive im- 
mune responses. We have previously demonstrated in immunogenic routine tumor models that 
bone marrow (BM)-derived DC pulsed ex vivo with synthetic tumor-associated peptides, nat- 
urally expressed by tumor cells, serve as effective antitumor vaccines, protecting animals against 
an otherwise lethal tumor challenge (Mayordomo, J. I., T. Zorina, W.J. Storkus, C. Celluzzi, 
L. D. Falo, C.J. Melief, T. lldstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze.  1995.  Nature 
Med.  1:1297-1302).  However, T  cell-defined epitopes have not been identified for most hu- 
man cancers. To explore the utility of this approach in the treatment of tumors expressing as 
yet uncharacterized  epitopes,  syngeneic  granulocyte/macrophage  colony-stimulating factor- 
stimulated  and  BM-derived  DC,  pulsed  with  unfractionated  acid-eluted  tumor  peptides 
(Storkus,  W. J.,  H.J.  Zeh III, R. D.  Salter,  and M.  T. Lotze.  1993.J.  lmmunother.  14:94-103) 
were used to treat mice bearing spontaneous, established  tumors. The adoptive transfer of 5  3(  105 
tumor peptide-pulsed DC dramatically suppressed the growth ofweaHy immunogenic tumors 
in day 4 to day 8 established MCA205  (H-2  b) and TS/A (H-2  a) tumor models, when applied 
in three biweeHy intravenous injections.  Using the immunogenic C3 (H-2  b) tumor model in 
B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tu- 
mors and long-term survival in  100%  of treated animals.  The DC-driven antitumor immune 
response was primarily cell mediated since the transfer of spleen cells, but not sera, from immu- 
nized mice efficiently protected sublethally irradiated naive mice against a subsequent  tumor 
challenge.  Furthermore, depletion of either CD4 + or CD8 + T  cells from tumor-bearing mice 
before therapy  totally suppressed the  therapeutic  efficacy of DC  pulsed  with  tumor-derived 
peptides. Costimulation of the host cell-mediated antitumor immunity was critical since inoc- 
ulation of the chimeric fusion protein CTLA4-Ig virtually abrogated the therapeutic effects of 
peptide-pulsed DC in vivo. The analysis  of the cytokine pattern in the draining lymph nodes 
and spleens  of tumor-bearing mice immunized with  DC  pulsed with  tumor-eluted peptides 
revealed a  marked upregulation  of interleukin  (IL)  4  and  interferon  (IFN) ~/  production,  as 
compared with mice immunized with DC alone or DC pulsed with irrelevant peptides. DC- 
induced antitumor effects were completely blocked by coadministration of neutralizing mono- 
clonal antibody directed against T helper cell  1-associated cytokines (such as IL-12, tumor necro- 
sis factor or,  IFN-~/), and eventually, but not initially,  blocked by anti-raiL-4 mAb. Based on 
these results,  we believe that DC pulsed with acid-eluted peptides derived from autologous tu- 
mors represents a novel approach to the treatment of established, weaHy imnmnogenic tumors, 
and serves as a basis for designing clinical trials in cancer patients. 
R 
ecent advances in  the  understanding  of antigen  pre- 
sentation,  antigen  recognition  requirements,  and  T 
cell activation have provided us with a mechanistic frame- 
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work allowing the modeling of novel immunotherapies for 
the treatment of cancer. Conceptually, an effective therapy 
capable of eliciting a cellular immune response should con- 
tain a series  of MHC-presented tumor peptide epitopes ca- 
pable of being recognized by T cells, provide adequate T cell 
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primary, and secondary lymphoid organs rich in naive T  cells. 
Several  reports  have  previously  demonstrated  that  tu- 
mor-specific CTL can be generated that recognize peptide 
epitopes presented on the tumor cell surface in the context 
of MHC  class I  molecules (1-4).  Tumors,  however,  have 
evolved various mechanisms to escape an immune response 
(1).  Class I  or antigen loss variants, secretion of immuno- 
suppressive agents, or lack of costimulation leading to anti- 
gen-specific T  cell clonal anergy (5) have all been identified. 
To  overcome these  states of immunotolerance,  cytokine/ 
costimulatory  molecule-engineered  tumor  vaccines  were 
generated and shown  to  be capable of eliciting long-term 
antitumor  immune  responses  in  many  cases  (6).  Effective 
cytokine gene  (i.e., GM-CSF, IL-4, IL-12)-transduced tu- 
mor  vaccines  have  been  characterized  to  induce  in  vivo 
initial influences of APC,  including dendritic cells (DC) l, 
with  subsequent  involvement  of lymphocytes  (7,  8).  For 
CD4 + T  cell priming T  cell priming, these APC are likely 
to ingest tumor Ags for processing and presentation in MHC 
class II complexes. Presentation of MHC  class I-restricted 
tumor antigens to CD8 §  T  lymphocytes was classically as- 
sumed to be presented by the cell naturally expressing the 
antigens, such as the tumor cell itself. However, recent evi- 
dence suggests that tumor cells are poor APC, and profes- 
sional  APC  may  be  essential  for  induction  of not  only 
CD4 + T  cells but also for a CD8 + T  cell-mediated antitu- 
mot immune response. Huang et al. (9) reported that the in 
vivo priming of MHC  class I-restricted responses involves 
a transfer of tumor antigens to a host bone marrow-derived 
DC (BM-DC) and subsequent presentation to CD8 § T  cell 
effectors. Moreover, a  correlation between  the number of 
presumptive  DC  infiltrating  a  cancer  and  longer  patient 
survival  or  reduced  frequency  of metastatic  disease  have 
been  observed for a  variety, of cancer types (10).  First de- 
scribed by Steinman and Cohn in 1973 (11), DC have been 
known to be highly specialized antigen-presenting cells and 
to  be  the  principal activators  of resting,  naive  T  cells in 
vitro and in vivo (12-15),  capable of efficiently transport- 
ing antigens from  the periphery to lymphoid organs.  DC 
pulsed  with  ovalbumin  (16)  or  viral peptides  (17),  lym- 
phoma-derived surface lg (18),  or tumor-derived synthetic 
epitopes (1a,18a)  and then  injected as a  vaccine have  been 
reproducibly shown  to  immunize  naive  animals  against a 
subsequent viral or tumor challenge. Defined tumor-derived 
T  cell epitopes are,  however,  currently available for study 
in only a limited number of human tumor types (i.e., mela- 
noma, ovarian, and breast carcinoma [1]). 
To investigate the potential utility of DC-based vaccines 
for the treatment of cancer patients whose  tumors  express 
as yet  uncharacterized  T  cell epitopes,  we  have  evaluated 
the therapeutic e~cacy ofunfractionated, MHC class I-eluted 
tumor  peptides  (19)  loaded onto  BM-DC  as  cancer  vac- 
cines in murine tumor systems. We show in three different 
tumor models in two  strains of mice that  DC  pulsed with 
IAbbreviations used in this paper: BM-DC, bone marrow-derived dendrinc 
cells; CM, culture medium; DC, dendritic cells; i.d., intradermal. 
tumor peptides induced an MHC  class I-restricted, T  cell- 
mediated antitumor immune response that (a) is capable of 
markedly suppressing or slowing the growth of established 
tumors,  (b) is completely dependent on  costimulatory sig- 
nals,  Thl-associated  cytokines,  and  requires  both  CD4 + 
and  CD8 +  T  cells,  (c)  is Th0-1ike  when  characterized for 
the  pattern  of cytokines elaborated in  response  to  tumor, 
and  (d)  confers  significantly  superior  protection  when 
transferred  to  naive  mice  if the  donor  lymphocytes were 
obtained from mice vaccinated with tumor peptide-pulsed 
BM-DC  coadministered with low doses of malL-12. 
Materials  and Methods 
BM-DC  Isolation and Peptide Pulsing.  Culture of BM-DC has 
been previously described (la, 20).  Briefly, lymphocyte-depleted 
mouse  bone  marrow  suspensions,  supplemented  with  rmGM- 
CSF +  trolL-4 (1,000  IU/ml each, DC media) for 5-8 d leads to 
the generation of large numbers ('J107/mouse) of functional DC 
as defined by morphology, ultrastructure, phenotype, and strong 
mixed lymphocyte reaction~timulating activity. The phenotype 
of BM-DC  typically included  high-frequency  expression  (60-- 
95%)  of CD45,  CD44,  CD11b,  CD18,  CD80,  and  CD86,  as 
well as MHC class I and class II antigens. Before use in vaccines, 
DC  were pulsed overnight with crude, acid-eluted tumor pep- 
tides from autologous tumors or unfractionated, acid-eluted pep- 
tides derived from syngeneic spleens, according to the procedure 
described below.  Peptide-pulsed DC  were  extensively washed 
and then  irradiated (3,000  rads)  before i_v. injection in  the  tail 
vein  of tumor-bearing  animals.  In  the  weakly  immunogenic 
MCA205 and TS/A tumor models, animals were injected three 
to four times, starting at day 4 or day 8 after tumor establishment 
and subsequently, every 4  d,  with 3-5  ￿  105  DC  pulsed with 
peptides.  Alternatively, in  the  imnmnogenic  C3  tumor model, 
animals were injected on days 14, 21, and 28 after initial intrader- 
real (i.d.) tumor inoculation. 
Pro~essively growing tumors (MCA205 and C3 in C57BL/6 
mice [B6] [H-2bl or TS/A in BALB/c [H-2d]) were surgically re- 
moved at day 20-25  ("q50-250  nun 2 in size),  and a single-cell 
suspension was obtained after brief enyzmatic digestion (60 min) 
with  DNase  I  (0.1  rag/nil;  #776785;  Boehringer  Mannheim 
Corp.,  Indianapolis, IN),  collagenase (1  mg/ml,  173  U/nag)  in 
AIMV  media  (GIBCO-B1KL,  Gaithersburg,  MD).  Viable cells 
("q-5  X  109/cells)  were  washed  three times in  HBSS  (Gibco 
Laboratories), and the cell pellet was treated with mild acid buffer 
to allow for rapid isolation of tumor-associated peptides, as previ- 
ously described (19).  Briefly, 10  ml of citrate-phosphate butler, 
pH =  3.3, was added at room temperature, and cell pellets were 
immediately resuspended by pipetting and centrifuged for 5 min 
at 1,000 g.  The cell-free supematant was harvested, and peptides 
in  acid-extracted supematants  were  concentrated  on  activated 
SepPak  C18  cartridges  (Millipore Corp.,  Bedford,  MA).  The 
bound material was eluted with 2-3 ml of 60% acetontrile in wa- 
ter and lyophilized to near complete dryness (i.e., 20-50 Ixl). The 
peptides were then reconstituted in  1 ml HBSS  (GIBCO-BRL) 
and stored frozen at  -20~  until used in  DC-pulsing experi- 
ments.  1  million BM-DC  were  pulsed  with  peptides  derived 
from  10  s to  109 minor cell equivalents ira a total volume of 1-2 
nfl of DC media overnight at 37~  5% CO2. 
Tumor  Cell  Lines  and  Mouse  Strains.  Female  6-8-wk-old 
C57BL/6  (B6)  and BALB/c (H-2  d) mice were purchased from 
The Jackson  Laboratory  (Bar  Harbor,  ME).  MCA205  (H-2t'), 
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[NCI], Bethesda, MD) is a methylcholanthrene-induced fibrosar- 
coma established in B6 ,nice. TS/A (H-2 d) is a tumor cell line es- 
tablished  by  P.  Nanni  (University  of Bologna,  Bologna,  Italy) 
from  the  first  in  vivo  transplant  of a  moderately  differentiated 
manmlary adenocarcinoma spontaneously arising in a 20-mo-old 
female  BALB/c  mouse  (21)  and  kindly  provided  by  G.  Fomi 
(Immunogenetic  and  Histocompatibility  Center,  Turin,  Italy). 
The meth A sarcoma is a methylcholanthrene-induced tumor es- 
tablished in H-2  d mice (22). C3 is a tumor cell line obtained by 
transfecting  C57BL/6  mouse  embryonal  fibroblasts  with  a  plas- 
nfid containing the entire genome of the human  papilloma virus 
type 16 (la). All tumor cell lines were maintained in RPMI-1640 
supplemented  with  10%  fetal bovine serum  (Life Technologies, 
Inc., Grand  Island,  NY),  2  mM L-glutamine,  100 U/ml penicil- 
lin, and  100  pug/ml streptomycin  (Whitaker Bioproducts,  Walk- 
ersville, MD), referred to henceforth as CM (culture medium). 
In  Vivo Tumor Therapy Models.  Twice the  nfinimal tumori- 
genic dose of tumor cells (2  X  10 ~ MCA205,  10 s TS/A, or 2  X 
10 ~ C3)  were  injected  i.d.  in  the  right  flank  of nfice.  Animals 
bearing day 4- to 8-established  MCA205 or TS/A tumors were 
treated with three to tbur biweekly (every 4  d)  i.v. injections of 
3-5  X  10 s syngenic BM-DC  prepared  as described above. Ani- 
mals bearing day  14-established  C3  tumors  were treated weekly 
with  syngeneic BM-DC  (3-5  X  l0 s)  pulsed  with  peptide.  The 
mean tumor size was monitored biweekly. All experiments were 
performed two  to  three times using individual treatment  groups 
of five mice. Mice were killed when tumors became ulcerated or 
when they reached a size >250 mm  2. 
Depletion Studies with Blockitg Antibodies.  CTLA4-Ig, a soluble 
fusion protein  composed of the  extracellular domain  of the  hu- 
man  CTLA4  receptor  and  the  Fc portion  of a  human  IgG1C~ 
chain has been previously described (23)  and was kindly provided 
by  G.  Davis  (Repligen  Corp.,  Cambridge,  MA).  50  pug  of 
CTLA4-IgG1 was admixed with DC-MCA205 or DC-TS/A in 
vitro, and  the mixture was then  administered  in the tail vein of 
tumor-bearing animals  (three to four injections every 4  d).  Mice 
treated  with  human  IgG  (Ganfimmune  N,  Miles  Laboratories, 
Inc.,  Elkhart,  IN)  were  used  as  controls.  Hamster  nkAbs  to 
mIFN-y (H22) and mTNF-ot (TN3  19.12)  were prepared as pre- 
viously  reported  (24).  The  C17.8  (kindly  provided  by  M. 
Wysocka [25],  The Wistar Institute,  Philadelphia,  PA) is an anti- 
mp40-IL-12-neutralizing  mAb  (rat  IgG2a),  which was  adminis- 
tered i.p.  (l  nag/mouse)  1 h  before the  first  two DC  injections. 
The  l lBll  (26;  rat  IgG2a)  (hybridoma  kindly  provided  by  G. 
Shearer,  NCI)  is a  neutralizing anti-rolL-4 mAb administered  by 
i.p. injections of 300  ptg/mouse 4  h before and then 24, 48, and 
72  h  after each of the first  two DC injections. Anti-CD4 (clone 
GK1.5,  rat  IgG2b)  (27)  and  anti-CD8  (clone  2.43,  rat  IgG2b) 
(28)  mAb  (kindly provided by M.  Brunda,  Hoffman-La Roche, 
Nutley, NJ) were injected i.p. on days 2 and 10 (1 nag/mouse/in- 
jection) after tumor inoculation.  Depletion of CD4 + and  CD8 + 
T  cells was  monitored by flow cytolnetry.  Nomlal rat  IgG was 
administered in negative control groups of animals. 
In Vitro Cytokine Release Assays.  Retroperitoneal lymph nodes 
(ipsi- and contralateral from the tumor)  and spleens of two nfice 
per  group,  in  two  different  experiments,  were  collected  after 
three  to  four  therapeutic  applications  (days  16-20).  Cells  were 
harvested after mechanical disruption  of tissue  in a  culture  dish, 
counted,  and  resuspended  in  CM  +  50  IU/ml rhlL-2  (Chiron, 
Emeryville, CA) at a final concentration of 1.5  ￿  106/ml. 200 p.1 
of cells/well were cocultured with 10 s irradiated MCA205 (5,000 
rads)  in 96-well flat-bottomed plates.  Plates  were  incubated  for 
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24 h  (for C57BL/6 mice) or 36 h  (for BALB/c mice) at 37~  5% 
CO2.  The  supernatants  (100  I.tl) were  harvested  and  assessed  in 
conunercial ELISAs for production of mlFN-',/and mlL-4 (Gen- 
zyme Corp., Cambridge,  MA). The lower limit of sensitivity for 
each assay was 47 and 30 pg/ml, respectively. 
Cytotoxicity Assays.  YAC-1  (kindly provided by W.  Cham- 
bers, University of Pittsburgh,  Pittsburgh,  PA), or the TAP-defi- 
cient T  lymphoma  RMA-S  (kindly  provided by  H.  G.  Ljunn- 
gren,  Massachusetts  Institute  of Technology,  Cambridge,  MA) 
were pulsed with  10  ILl of splenic or MCA205-derived peptides 
and labeled in CM containing Na2SlCrO4 (150 puCi/nfillion cells) 
for 1-2 h at 37~  washed twice, and resuspended in CM at 2  X 
105 cells/ml. MCA205 target cells were labeled in the same way. 
Equal  volumes  (100  pul) of target  (admixed  1:10  with  YAC-I 
cold target  provided  to  diminish  nonspecific  LAK activity)  and 
effector cells (i.e., splenic cells after 5-d in vitro restimulation at 
effector-to-S~Cr-labeled-target  ratios  of 40:1  and  1(1:1)  were 
plated  in  triplicate  round-bottomed  microtiter  wells  for  4  h  at 
37~  5% CO2. After a 4-h incubation,  100 gl ofsupernatant was 
collected, and  the percentage  of specific S~Cr release was  calcu- 
lated using the following formula: percent 5tCr release  =  100  X 
(cpm  experinient  -  cpm  spontaneous  release)/(cpm  maxinmm 
release  -  cpm  spontaneous  release),  where  spontaneous  release 
was that obtained from target cells incubated with medium alone, 
and maximum release was obtained from target cells incubated in 
5%  Triton  X-100  (Sigma  Chemical  Co.,  St.  Louis,  MO).  The 
specificity of tumor-directed  cytotoxicity was  evaluated  by  the 
addition  of mAb specific for H-2K  b (28-13-35:  American Type 
Culture Collection, Rockville, MD), H-2D b (28-11-55; ATCC), 
and anti-mCD3 (29B; GIBCO-BRL). 
lmmunohistodlemistry.  Mice were killed by asphyxiation with 
CO2  gas.  Tissue from tumor sites  was  removed and  placed in a 
cryomold filled with OCT-embedding medium (Miles Laborato- 
ries  Inc.).  Tissues were snap-frozen by placing the mold on dry 
ice. Thin sections  (5-7  ~m)  were cut by cryostat and placed on 
slides.  Slides were stored at  -80~  or were immediately stained. 
Routine  hematoxylin-eosin  staining  was  performed  on  all  tis- 
sues.  Cryostat  sections  were  fixed in  cold acetone,  hydrated  in 
PBS,  and  incubated  in  protein-blocking  solution  (Inununon; 
Shandon-Lipshaw,  Pittsburgh,  PA)  for  8  ram.  They  were  then 
incubated  overnight  at  40~  with  rat  mAbs  directed  against 
mouse CD4  (TIB207;  ATCC)  and  CD8  (TIB210;  ATCC).  Iso- 
type-matched rat lgG was used as a negative control. Positive tis- 
sue controls consisted of frozen sections of spleens from BALB/c 
and B6 mice. After buffer washes, endogeneous peroxidase activ- 
it  3, was quenched with 0.6% H202 in methanol. Species-absorbed 
biotinylated  mouse  anti-rat  F(ab')2  (Jackson  ImmunoResearch 
Laboratories,  Inc.,  West Grove, PA)  was  applied  to sections  in- 
cubated  with  unlabeled  prinlary  Ab  followed  by  treatment 
with streptavidin-peroxidase  (Boehringer Mannheim Corp.)  and 
3'-anfino-9-ethylcarbazole  (Biomeda  Corp.,  Foster  City,  CA). 
Sections were  counterstained  with  hematoxTlin and  mounted  in 
CrystalMount (Biomeda Corp.). 
Statistical Analyses.  Fisher's  exact method  was  performed  to 
interpret  the  significance  of differences  between  experimental 
groups  (presented  as mean  +  SEM).  Significance at 95%  confi- 
dence limits are presented for individual experiments. 
Results 
DC Pulsed with Acid-eluted Peptides Derived  from Syngeneic 
Tumors  Markedly  Inhibits  Tumor  Progression in  Alice Bearing 
Weakly Immunogenic Tumors.  Twice  the minimal tumori- genic  dose  of tumor  cells MCA205  were  injected i.d.  in 
the flank ofsyngeneic C57BL/6 mice on day 0.4-8  d later, 
animals  bearing  established  tumors  (,'o10-15  mm  2  to  35 
mm  2 in size, respectively) were treated three to four times 
with biweekly i.v.  administration of 3-5  X  10 s  irradiated 
BM-DC  prepulsed  with  either  unfractionated  MCA205 
tumor-  or  unfractionated  B6  spleen-derived  acid-eluted 
peptides. As depicted in  Fig.  1 A, the mean  tumor size in 
the day 4  established tumor group injected with DC pulsed 
with the relevant MCA205-derived peptides is significantly 
smaller  than  the  control  groups  (albumin,  DC  alone,  or 
DC  pulsed  with  splenic  peptides)  at  all  therapeutic  time 
points. Whereas no animals were tumor free after three im- 
munizations,  in  most  cases,  the  tumor  growth  was  sup- 
pressed within 7  d  after the first immunization.  Indeed, the 
tumor size remained static for >6 wk. Whereas control an- 
imals  were  sacrificed  at  day  20,  animals  receiving  DC- 
tumor peptide therapy survived for 8-10 wk. Most of these 
antitumor effects can be attributed to the first two DC im- 
munizations  (data  not  shown).  Tumor  growth  was  also 
markedly reduced  when  the  first therapeutic  injection  of 
DC-MCA205  was started later (day 8)  (Figs. 1 A  and 2  B). 
Essentially  identical  results  were  achieved  in  the  TS/A 
(H-2  d)  established  tumor  model  (poorly  immunogenic 
mammary adenocarcinoma) in BALB/c mice (Fig. 1 /3). In 
a  more immunogenic model  (i.e., C3),  tumors  established 
for 14 d were successfully treated with DC pulsed with un- 
ffactionated acid-eluted peptides administered on days  14, 
21,  and 28. All DC-tumor  peptide-treated animals exhib- 
ited complete and sustained tumor regressions (Fig. 1  C). 
Coadministration of Low Doses of Systemic rmlL-12 Modu- 
lates DC-mediated  Antitumor Effects by Enhancing the Memory 
Response.  Macatonia et al. (29) recently reported that DC 
produce  IL-12  and  direct  the  development  of Thl  cells 
from naive  CD4 +  T  cells in vitro.  This finding prompted 
us  to  evaluate  whether  concomitant  systemic  administra- 
tion of low doses ofrmlL-12  (100  ng provided i.p. every 
4  d)  would  augment  the  efficacy  of DC-tumor  peptide 
therapy in our in vivo models using poorly immunogenic 
tumors.  As  shown  Fig.  2,  A  and  B,  despite  a  beneficial 
therapeutic effect ofrmlL-12 alone in day 4  (but not day 8) 
tumor  models,  the  coadministration  of  IL-12  and  DC- 
MCA205  did  not  result  in  a  statistically significant  im- 
provement over groups treated with DC-MCA205  alone, 
although  the  tumor  growth  curves  were  reproducibly 
slower  for  the  DC-MCA205  +  rmIL-12  group  in  three 
independent experiments. However, DC-MCA205  +  rmlL- 
12 is significantly superior to administration of IL-12 alone 
+  DC  or DC  pulsed with  irrelevant splenic peptides for 
the treatment of established day 8 tumors (Fig. 2  B). 
To  verify that DC-MCA205-induced  antitumor  effects 
stem from the activation of the host immune system and to 
further evaluate the  effects of combined IL-12 administra- 
tion on the in vivo priming ofT  cells, adoptive transfer ex- 
periments were  performed.  Sera  and/or spleens were  ob- 
tained from day 16-18  treatment groups  and injected into 
sublethally irradiated naive littermates. As shown  in  Fig. 2 
C,  neither  pooled  sera  from  mice  immunized  with  DC 
Figure  1.  BM-DC  pulsed with  unfractionated, acid-eluted peptides 
derived from tumors but not from syngeueic spleens induce potent anti- 
tumor effects in vivo in mice bearing day 4-8 weakly immunogenic fi- 
brosarcoma MCA205 or mammary adenocarcinorna  TS/A, or day 14 im- 
munogenic C3 tumors. 2 ￿  105 tumor cells MCA205 (A), 105 TS/A (/3), 
or 2 ￿  106 C3 (C) were injected i.d. in one flank of C57BL/6 or BALB/c 
mice, respectively.  Tumor-bearing mice were given three to four i.v. im- 
munizations with BM-DC, beginning on day 4 or day 8 and repeated ev- 
ery 4 d (MCA205, TS/A) or every 7 d beginning on day 14 (C3). Before 
their in vivo injection, the BM-DC were pulsed with acid-eluted tumor 
peptides (DC-MCA205,  DC-TS/A, DC-C3)  or splenic peptides (DC- 
spleen B6 or BALB/c) overnight, or were not pulsed with peptides (DC). 
DC preparations were irradiated (3,000 rads) and washed to remove un- 
bound peptides before i.v. injection of 3-5 ￿  10  s DC/mouse.  Mean tu- 
mor size +  SE of five mice per group, pooled from three different exper- 
iments, are depicted over time. Significant results at 95% (Fisher's exact 
method) are indicated (*). 
alone or DC pulsed with splenic peptides (control groups), 
nor sera pooled from mice immunized with DC-MCA205 
on day 4  or day 8  (from mice depicted in Fig. 1) were ca- 
pable  of transferring  significant  protective  antitumor  im- 
munity.  All mice  were  killed at  day  15  with  primary tu- 
mors  >250  mm  2  and  demonstrable  metastatic  disease. 
Conversely, the transfer of 107 pooled, cryopreserved sple- 
nocytes derived from DC-MCA205  day 4  or 8  treatment 
groups  was  reproducibly  capable  of significantly slowing 
tumor  growth  in  these  naive  syngeneic  mice  (Fig.  2  D) 
90  Cancer Therapy Using Dendritic Cell-based Vaccines Figure 2.  Coadministration of low doses  of rmlL-12 does not signifi- 
cantly  enhance the DC-MCA205-mediated antitumor response but aug- 
ments the efficacy of adoptive transfer  of immune cells. 50 ng of rmlL-12 
was administered i.p.  on the day of the DC injections and  1 d after DC 
injections,  starting on day 4  (A) or day 8 (B). Mean tumor size  +  SE of 
five  mice per group, pooled from three  different  experiments, are  de- 
picted over time. Significant  results at 95% (Fisher's exact method) are in- 
dicated  (*)  and  support the  therapeutic  advantage  of DC-MCA205  or 
DC-MCA205  +  IL-12 over DC +  IL-12 or IL-12 alone only in the case 
of the day 8 model. (C) DC-MCA205-mediated antitumor effects are not 
dependent on humoral immunity. Sublethally  irradiated  (500 rads) synge- 
neic mice (day  -4) were injected  with 200  OA of pooled sera  (day  -2, 
day  -1)  from immunized mice  (DC alone  +  traiL-12,  DC-spleen  + 
rrnlL-12, or with DC-MCA205 day 4 or day 8 •  rmlL-12, and bled after 
three to four inmaunizations),  and subjected to a lethal  tumor challenge 
on day 0. Tumor growth was monitored. No significant  benefit from the 
adoptive transfer  ofsera was observed. (D) DC-MCA205-mediated anti- 
tumor response is  transferred  by  splenocytes  derived  from immunized 
mice. Sublethally  irradiated  (500 rads) syngeneic mice (day -4) were in- 
jected with 107 spleen cells from pooled cryopreserved spleens  (day  -1) 
from immunized mice (DC alone •  traiL-12, DC-spleen -+ rmlL-12, or 
with DC-MCA205  day 4 or day  8  •  rmlL-12, and killed  after  three to 
four immunizations) and subjected to a lethal  tumor challenge  on day 0. 
Established  tumor  growth  was  monitored.  Significant  results  at  95% 
(Fisher's  exact method) are indicated  (*). 
flanks of sublethally irradiated BALB/c  mice. Whereas the 
growth of TS/A  was inhibited by  the adoptive  transfer of 
cells derived from mice immunized with DC-TS/A,  there 
was no impact of this treatment on the growth of the "ir- 
relevant" meth A  sarcoma (data not shown). 
These  in  vivo  results  were  reflected  in  in  vitro  studies 
quantifying the specific cytolytic activity of in vivo primed 
CTL present in the spleens of mice immunized three times 
with  DC-MCA205  or  DC-spleen  +  rmlL-12.  Spleno- 
cytes  were  restimulated  for  5  d  in  vitro  with  irradiated 
MCA205  tumors. After this restimulation,  the splenocytes 
from  mice  immunized  with  DC-MCA205  and  DC- 
MCA205  +  rmlL-12  displayed  significantly  elevated  cy- 
tolytic  reactivity  against  MCA205  (Fig.  3,  A  and  B)  that 
was inhibited 50-60%  by anti-H-2K  b and H-2D b antibod- 
ies  or by  anti-CD3  (data  not shown).  These  effector  cells 
did  not  lyse  the  murine  LAK-sensitive  target  RMA-S. 
Splenocytes derived from mice receiving DC-MCA205  + 
rmlL-12 typically displayed greater cytolytic reactivity than 
splenocytes from DC-MCA205  alone (Fig. 3 A). 
compared  with  control  groups.  Interestingly,  the  survival 
was even more prolonged in the groups receiving spleno- 
cytes  derived  from  tumor-bearing  mice  immunized  with 
DC-MCA205  day  4/8  +  rmlL-12  compared with  those 
mice immunized with DC-MCA205  on day 4  or 8  alone. 
There was no additional protective advantage ofcotransfer- 
ring sera  along with  splenocytes  in  these  groups  (data  not 
shown). We conclude that DC pulsed with acid-eluted tu- 
mor  peptides  promote  efficient  cellular-mediated  antitu- 
mot immunity  and  that  coadministration of low  doses  of 
rmlL-12  may favor the priming  of tumor-specific  T  cells. 
Analogous  results  were  achieved  in  the  TS/A  model  in 
BALB/c  mice  (data  not shown).  To  test the specificity  of 
the immune response elicited by the DC-TS/A,  105 TS/A 
and 105 meth A  sarcoma cells were injected s.c. in opposite 
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Figure  3.  MCA205-specific CTL are generated in the spleens of mice 
immunized three to four times with DC pulsed with MCA205-derived 
tumor  peptides  (DC-MCA205)  but  not  with  splenic  peptides  (DC- 
spleen) or control DC (DC). Two spleens per group were harvested  at day 
16-18, with restimulation in vitro for 4-5 d with irradiated  MCA205 tu- 
mor cells, before use as effector  cells in 4-h SlCr release assays. Targets in- 
cluded SlCr-labeled  MCA205  and the NK/LAK target  cell hne RMA-S 
(data not shown). The results of two representative experiments (A and B) 
are  shown.  Results  are  reported  in  lytic  units  per  spleen  against  the 
MCA205 target cell as outlined in Materials  and Methods. Significant  re- 
suits at 95% (Fisher's  exact method) are indicated  (*). Table  1.  Dendritic  Cells Pulsed with Acid-eluted Tumor Peptides blduce a ThO-associated Immune Response in the Draining Lymph Nodes 
and Spleens in B6 Mice 
Nodes  Spleens 
Mean Tumor 
Groups  size (nm12) D23  mlL-4 ~  mlFN-y*  mlL-4*  mlFN-y* 
DC or DC-spleen  145  _+  19  5  ---  1  0  --- 0  6  +  l  643  +  460 
DC or DC-spleen  +  IL-12  70 +  213  10 +  5  17  _+  12  6  _+  1  194 +  90 
DC-MCA205  65  +-  10  :~  162 +  78*  379  4- 226*  79 +  21'  1,515  +  143 
DC-MCA205  +  IL-12  48  +  5'-';  24  +  9 !i  1,229 +  702~;  38  +  5~  6,666  _+ 760~ 
Retroperitoneal lymph nodes (ipsi- and contralateral fi'om the tumor) and spleens  of two mice per group, in two different experiments, were col- 
lected after three to four therapeutic applications (days 16-20). Cells were harvested and cocultured with 105 irradiated MCA205 (5,000 rads) in 96- 
well flat-bottomed plates. Plates were incubated for 24 h at 37~  5%. CO,. The supernatants were harvested and assessed in commercial ELISAs for 
production of mlFN-"/and mlL-4. Mice bearing day 4 MCA205 tumors were treated with either DC, DC pulsed with normal splenic acid-eluted 
peptides, or DC pulsed with acld-eluted MCA205 peptides. Identical treatment groups were also provided systemic traiL-12 as indicated in Materi- 
als and Methods. Due to the lack of statistical difference between groups treated with DC alone amid DC pulsed with acid-eluted splenic peptides 
(DC-spleen), and the same groups provided systemic  rlL-12, we have combined their data and report mean and SE in this table. 
*pg/ml/2 X  106 cells/24 h in Elisa +  SE. 
*Significant at 95% (Fisher's exact method) versus DC/DC spleen. 
3Significant  at 95% (Fisher's  exact method) versus DC/DC spleen +  IL-12. 
hnmmlizations  with  DC  Pulsed  with  Acid-eluted  Peptides 
Enhance  Cytokine  Release from  the  Tumor-draining  Lymph 
Nodes and in the Spleen  in Response to Tumor.  Since cellular 
immunity  appeared  to  be  critical  in  mediating  antitumor 
effects,  we  analyzed the pattern of cytokines  released in an 
in vitro recall response to MCA205  tumor by ceils derived 
from  the  retroperitoneal  draining  lymph  nodes  and  from 
the  spleens  of DC-treated  tumor-bearing  mice  (Table  1). 
Freshly  isolated  mononuclear  cells  were  cultured  for  24  h 
in  vitro  in  the  presence  of MCA205  rumor.  The  culture 
supernatant was then analyzed by ELISA for levels of rolL-4 
and  mlFN-y  production.  As  expected,  a  Thl-associated 
response  was  observed,  with  a  significant  enhancement  of 
mlFN-y  production in the DC-MCA205  treatment groups. 
Interestingly,  levels  of  the  Th2-associated  cytokine  IL-4 
were also dramatically elevated in the same groups.  In vivo 
administration of IL-12  did  not  significantly alter  these  in 
vitro  results.  Similar  results  were  observed  for  lymphoid 
cells derived from TS/A  tumor-bearing BALB/c  mice (Ta- 
ble 2). 
Senfiquantitative  reverse  transcription  PeR  performed 
on  snap-fi'ozen  specimens  suggested  that  DC-MCA205 
therapy results in upregulation of messages encoding raiL-4, 
rolL-5,  raiL-10,  mlFN-y,  and  mp40-IL-12  in  situ  in  the 
nodes  of treated  mice  (data  not  shown).  Interestingly,  no 
discernible  qualitative  differences  in  cytokine  production 
were  noted  between  the  ipsilateral  nodes  and  their  con- 
tralateral counterparts.  In contrast to  the modulation  of cy- 
tokine messages in the lymphoid organs of DC-MCA205- 
treated  animals,  there  was  no  marked  difference  in  cyto- 
kines produced in situ within tumor lesions in mice derived 
from any of the treatment groups. 
Table 2.  Dendritic  Cells Pulsed with Acid-eluted Tumor Peptides hlduce a ThO-associated hmnune Response in the Draininr Lymph 
Nodes and Spleens in BALB/c Mice 
Nodes  Spleens 
Mean Tumor 
Groups  size (nm@ D23  mlL-4*  mlFN-y*  mlL-4*  mlFN-'y* 
DC or DC-spleen  124  +  45  32  +  15  182  +  1(16  224 +  25  5,485  +  1,502 
DC or DC-spleen  +  IL-12  79  _+ 20  31  _+ 23  651  +- 432  237  -4- 55  7,563  -+ 468 
DC-TS/A  27  +  10'  268  +  104'  5,000  •  120'  412  -  80*  15,000  _+ 376* 
DC-TS/A  +  IL-12  0  316'  9,000'  273  15,000' 
FZetroperitoneal  lymph nodes (ipsl- and contralateral from the tumor) and spleens  of two mice per group, in two different experiments, were col- 
lected after three to four therapeutic applications (days 16-20). Cells were harvested and cocultured vr  10  s irradiated MCA205 (5,000 rads) in 96- 
well flat-bottomed plates. Plates were incubated for 36 h at 37~  5% CO 2. The supernatants were harvested and assessed in commericial ELISAs for 
production ofmlFN-y and raiL-4. Mice bearing day 5 TS/A tumors were treated with DC-based therapies as outlined and reported in Table l. 
*pg/nfl/2 ￿  lff' cells/36 h in Elisa -+ SE. 
*Significant at 95% (Fisher's exact method) versus DC/DC spleen -+ IL-12. 
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Involved in the DC-mediated Antitumor Effects.  Our BM-DC 
cultures (5-8 d  in IL-4 +  GM-CSF) express high levels of 
the  costimulatory molecules CD80  and  CD86  (la).  Since 
costimulation  of T  cell-mediated antitumor  immunity  is 
critical for tumor rejection in vivo (30;  Zitvogel, L., P. D. 
Robbins, W. J.  Storkus,  M. J.  Maeurer,  1<.  L.  Campbell, 
M.  I~.  Clarke, R.  D.  Schreiber,  C.  G.  Davis,  H.  Tahara, 
and  M.  T.  Lotze,  manuscript  submitted  for  publication), 
we  investigated the  role  of these  costimulatory molecules 
in  the  DC-MCA205-mediated  antitumor  effects  by  ad- 
mixing and  coinjecting DC-MCA205  with  the  chimeric 
fusion  protein  CTLA4-Ig  i.v.,  which  functionally blocks 
Figure 4.  Induction of an effective immune response by tumor pep- 
tide--pulsed  DC requires CD4 + and CD8 + T cells, costimulation by B7, 
and IL-12, as well as its elicited cytokines, IFN-"/ and TNF-c~. For the 
four panels, the mean tumor size •  SE (five mice/group)  over time is 
shown.  The  experiment depicted is representative of two  experiments 
performed. Significant results compared with DC pulsed with MCA205 
peptides (solid squares) at 95%  (Fisher's exact method)  are indicated (*). 
The open squares represent DC pulsed with splenic peptides. (A) Costim- 
ulatory molecules (i.e., CD80  and CD86  expressed on immature BM- 
DC-MCA205)  are critical for promotion of an efficient therapy-induced 
antitumor immune response: DC-based therapy is completely abrogated 
by systemic applications  of CTLA4-Ig. 50 lag of the chimeric fusion pro- 
tein  CTLA4-IgG1  was  admixed with DC-MCA205  in vitro  and  the 
mixture administered i.v. on  day 4,  8,  12, and 16.  (B) DC-MCA205- 
mediated antitumor  effects are partially or completely abrogated by in 
vivo depletion of the Thl-associated  cytokines mlFN-~/ and mTNF-cr 
and by anti-raiL-12.  1 nag of neutralizing C17.8 (rat IgG2a anti-mp40- 
IL-12) or 350 lag ofanti-TNF-cr  + anti-IFN-'y mAb were injected i.p. 1 h 
before the first and second immunization with DC-MCA205 and on days 
3, 10, and 17, respectively. (C) DC-MCA205-induced antitumor effects 
are partially inhibited by in vivo depletion of the Th2-associated cytokine 
mlL-4.  300 lag of 11Bll  (rat IgG2a, anti-mlL-4)  was administered i.p. 
every day starting 4 h before the first DC immunization for 8 d. (D) DC- 
MCA205-induced  antitumor effects are completely inhibited by in vivo 
depletion of either the CD4 + or CD8 + T  cell subsets. 1 mg/mouse  of 
neutralizing anti-CD4  or anti-CD8  mAb or both was injected i.p. into 
tumor-bearing  mice  2  d  before  the  first immunization  with  DC- 
MCA205 and repeated 10 d later. 
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CD28/CTLA4-mediated  T  cell costimulation, on  days 4, 
8,  12, and 16. As depicted in Fig. 4 A, CTLA4-Ig adminis- 
tration markedly reduced the antitumor therapeutic impact 
of DC-MCA205  treatment, such that it was no longer sta- 
tistically significant versus control groups. 
To assess the relevance of our in vitro cytokine data (Ta- 
bles 1 and 2) in the therapy-induced antitumor immune re- 
sponse  in  vivo,  we  treated  the  animals  with  neutralizing 
antibodies reactive with Thl-derived cytokines (Fig. 4  B). 
The  coadministration  of  mAb  anti-TNF-a  and  anti- 
mlFN-%  or  anti-raiL-12,  completely  abrogated  DC- 
MCA205-mediated antitumor effects. However, when the 
first injection of blocking anti-mlL-12 antibodies was  in- 
jected after the first immunization with DC-MCA205  was 
performed, the inhibition of therapeutic effects was not sig- 
nificant, stressing the importance of the first vaccination for 
priming antitumor  CTL.  Further  immunizations may not 
be critical to amplify the recruitment of additional prime T 
cells, but perhaps  to  maintain  or expand memory T  cells, 
which  are not critically dependent on antigen-specific co- 
stimulation.  Since  high  levels of mlL-4  production  were 
measured in  the  draining lymph nodes  and the  spleens of 
the mice treated with and responding to three to four DC- 
MCA205  or DC-TS/A  peptide immunizations, we inves- 
tigated whether  this  Th2-associated  cytokine  affected the 
observed  antitumor  therapeutic  response  in  vivo.  The 
11Bll  (anti-raiL-4) mAb was injected before the first DC- 
MCA205  injection and  on  a  daily basis thereafter for 8  d. 
Although  tumor  volumes  were  greater  in  11B11-treated 
mice, the difference did not appear significant at day 10 af- 
ter  tumor  inoculation,  compared  with  the  control group 
receiving DC-MCA205  therapy and injected with normal 
rat serum  (Fig. 4  C).  However,  by day  16,  the  difference 
started to appear significant at 95% (Fisher's exact method). 
This  suggests  that  therapy-induced  IL-4  may  not  play  a 
dominant  role  in  the  priming of a  specific antitumor  im- 
mune  response  by the  DC-MCA205,  but  that  it may be 
implicated in  maintaining and/or  amplifying the  induced 
antitumor  immune  responses  (Tables  1  and  2).  As previ- 
ously  shown  (31),  IL-4  can  synergize with  IL-12  in  en- 
hancing the proliferation of antigen-specific Thl  clones. In 
our models, IL-4 may cooperate with coinduced Thl-asso- 
ciated cytokines in promoting antitumor immunity. 
CD8 + T  Cells as well as CD4 + T  Cells Are Required  for the 
Priming and~or  the E ffector Phase of the DC-mediated Antitumor 
Immune  Response  In  Vivo.  We  have  previously  demon- 
strated in our adoptive transfer experiments (Fig. 2  D)  that 
DC-MCA205  induced  cell-mediated  immune  response, 
protecting naive animals from a subsequent MCA205  chal- 
lenge. Further, DC, arguably the best APC for priming na- 
tive CD4 +  T  cells in vivo  (11-15),  elicited potent antitu- 
mor  CTL  responses  (Figs.  3,  A  and  /3)  in  our  in  vitro 
studies.  We  next  implemented  in  vivo  depletion  studies 
with  neutralizing  anti-CD4  and/or  anti-CD8  antibodies, 
performed early after tumor inoculation, in order to  assess 
the relative contribution of CD4 + and CD8 + T  cells in the 
observed therapeutic effects. Both T  cell subsets are impli- 
cated in DC-MCA205-induced  antitumor immunity since both anti-CD4  or anti-CD8  antibodies abrogated the anti- 
tumor therapeutic  response  (Fig.  4  D).  The inhibition  was 
significantly greater (Fisher's exact method,  at 95%) by day 
16,  when  both  anti-CD4  and  anti-CD8  antibodies  were 
added,  compared with that achieved with either one alone, 
suggesting a  cooperativity between both subsets  of T  cells 
in the DC-MCA205-mediated  antitumor effects. 
hnmunohistochemistry  analysis  documented  a  marked 
perilesional  and  intratumoral  infiltration  of CD8 +  T  cells 
(and  to  a  lesser extent  of CD4 +  T  cells)  at day  16  in  the 
groups  treated  with  DC-MCA205  (data  not  shown),  but 
not  in  those  treated  with  DC  pulsed  with  irrelevant  pep- 
tides. 
Discussion 
Since  Coley's first attempts to design therapeutically rel- 
evant tumoricidal  cancer vaccines  (31a),  significant insight 
into those parameters critical to the induction  and mainte- 
nance  of an antitumor immune  response  has been  gained. 
The current  consensus  is that (a)  T  cells can recognize  tu- 
mor peptides derived from cellular antigens (1 and  la, 2-4, 
32),  (b)  efficient  priming  of antitumor  immune  responses 
results  from  collaboration  of  APC  and  tumor-specific 
CD4 + and  CD8 + T  cells, and  (c) DC  are the most potent 
APC  for priming  antigen-specific  T  cells  in  vivo  and  in 
vitro (11-15).  Strategically located at sites of antigen expo- 
sure,  DC  efficiently internalize  and process/present soluble 
antigen.  This is particularly  true for DC  progenitors,  such 
as  those  generated  in  bone  marrow  cultures  containing 
GM-CSF (33-35). 
The  concept  of using  tumor  antigen-pulsed  APC  as  a 
means to elicit antitumor immunity is not novel (1  and  la, 
36).  DC are ubiquitous  in tissue and in blood,  but their ex 
vivo  expansion  in  large  numbers  has  been  difficult,  until 
the recent descriptions of methods to generate cultured DC 
(20,  35,  37-40).  Previous  studies  have,  indeed,  demon- 
strated  the  capacity of vaccines  to  elicit protective  antitu- 
mor  immune  responses  in  naive  animals  using  various 
forms  of tumor  antigens  and  diverse  types  of normal  and 
transformed  APC  (18,  18a,  41,  42).  The  novelty  of the 
present  study  is  the  use  of unfractionated,  acid-eluted  tu- 
mor peptides  derived  from  tumors  grown  in  vivo,  rather 
than synthetic peptides,  in conjunction  with DC grown in 
IL-4  +  GM-CSF  (la)  to serve as a  therapy for established 
tumors.  This protocol may effectively translate into human 
clinical  trials  designed  to treat patients  with  diverse tumor 
histologies. 
Although some genes encoding specific tumor-associated 
antigens  recognized  by  CD8 +  T  cells  have  been  recently 
cloned and the relevant antigenic  peptides have been iden- 
tified (la, 2-4),  the vast majority of the histologic subtypes 
of cancers  express  as  yet  undefined  tumor  epitopes.  Fur- 
ther, an optimal host antitumor T  cell response may require 
coordinate oligoclonal effector populations for the recogni- 
tion of a broad spectrum of tumor epitopes rather than re- 
sponses restricted  to a  single tumor-associated  determinant 
(la).  Given such  complexities,  we have evaluated whether 
unfractionated  tumor-eluted  peptides  (containing  multiple 
presumptive  T  cell  epitopes)  derived  from autologous  tu- 
mors of different histology and mouse strains can elicit effi- 
cient antitumor immunity when presented in vivo by syn- 
geneic  BM-DC.  We  have  demonstrated  that  DC  loaded 
with acid-eluted tumor peptides can drive a Th0-associated 
immune  response  in  vivo,  leading  to  the  suppression  of 
growth of poorly immunogenic  tumors. 
Although  our  method  for  generating  tumor-derived 
epitopes  effectively extracts  MHC  class  I-bound  peptides 
from the  tumor  cells  (19),  it  is likely  that  MHC  class  II- 
bound  tumor peptides  or cell-associated proteins  may also 
be  eluted.  Indeed,  each  of the  tumor  cell  lines  evaluated 
expressed  low  to  moderate  levels  of MHC  class  II when 
grown  in  vivo  (data  not  shown).  DC  priming of class  II- 
restricted  antitumor  immune  responses  is  circumstantially 
supported  by our ability to  significantly reduce  the  thera- 
peutic  efficacy of DC-MCA20S  in tumor-bearing animals 
by depletion ofCD4 + T  cells (Fig. 4  D). We are currently 
evaluating  the  specific  impact  of affinity-purified  MHC 
class  I- and  class II-derived tumor peptides in each of our 
tumor models.  Of interest,  acid-elution  ofpeptides  (which 
does not result in significant cellular lysis)  yielded a superior 
immunogenic  source  of DC-presented  epitopes  than  pep- 
tides extracted frond cells by repeated cycles of freeze-thaw 
lysis  (data  not  shown).  This  latter method  presumably re- 
sults in an unsuitably complex mixture ofpeptides that may 
be  further  complicated  by the  release  of intracellular  pro- 
teases.  Such  peptide  complexity would  be likely to  dilute 
the effective loading of a sufficient threshold density of rel- 
evant T  cell epitopes into MHC molecules expressed by DC. 
Preliminary  studies  stress  that  DC  pulsed  with  specific 
peptides injected i.v. do not traffic to the tumor itself (36). 
Rather,  DC injected  i.v. localize within  the  reticuloendo- 
thelial system (liver, spleen, and lymph nodes).  Indeed,  the 
tumors expressed the same cytokine pattern  (IFN-y and  IL- 
10 nflkNA in reverse transcription  PCR,  data not shown), 
in  effective treatment groups and  in  control groups.  Con- 
versely,  in  tumor-bearing  mice treated  with  three  to  four 
i.v.  injections  of DC  pulsed  with  acid-eluted  tumor pep- 
tides,  the ipsi- and the contralateral lymph nodes displayed 
similarly elevated production  of both Thl-  and Th2-asso- 
ciated  cytokines  compared  with  controls,  supporting  the 
systemic  effects of the  DC-based  therapy.  This  result  may 
support  a  molecular  dialogue  between  DC-T-B  cells 
within  lymph  nodes  involving  DC-synthesized  cytokines 
and  costimulatory molecules,  resulting  in  the  induction  of 
an antitumor immune response. 
In vitro data suggest that DC produce IL-12 and direct a 
Thl  imnmne response in naive CD4 + T  cells (29).  Further 
costimulation ofT  cells with B7-1,  IL-6, and IL-12 (all ex- 
pressed  by  DC)  is  sufficient  to  generate  antigen-specific 
CTL from naive splenocytes in a mixed lymphocyte tumor 
culture  (43).  We  were  able to  demonstrate  a  specific class 
I-restricted cytolytic activity from the spleens of mice vac- 
cinated with DC pulsed with relevant tumor peptides  (Fig. 
3),  suggesting  that  a  CTL  response  was  elicited  by  the 
transfbrred DC in vivo. 
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in  the  therapeutic  effects of DC  vaccines were supported 
by our ability to neutralize the  effectiveness of therapy by 
injection  of CTLA4-Ig and  neutralizing  Ab  anti-mp40- 
IL-12  in  vivo.  IL-12  is  a  potent  inducer  of IFN-y  and 
TNF-oL  production  by  both  NK  cells  and  T  cells  (44). 
IFN-~/ and TNF-ot are Thl-associated cytokines critically 
involved in the development of cell-mediated immune re- 
sponse  (45).  The  neutralization  of both  cytokines  totally 
abrogates the DC-induced antitumor response. These two 
cytokines simply account for the role of IL-12 in facilitat- 
ing  the  observed  immunoreactivity.  Interestingly,  when 
the anti-mlL-12 Abs were administered after the first  im- 
munization  with  DC  pulsed  with  the  relevant  peptides, 
rather than before the first immunization, the I)C-induced 
antitumor effects were not significantly affected, suggesting 
that as few as  5  ￿  105  DC/mouse  can prime a  sufficient 
number of naive  T  cells  to  affect tumor growth  and  that 
subsequent immunizations may play a role in amplifying or 
maintaining these "memory" antitumor T  cells. 
Increases in II,-4 production from draining lymph nodes 
and spleens were noted in groups of mice receiving three 
to four in vivo immunizations with DC pulsed with tumor 
peptides  compared  with  DC  pulsed  with  irrelevant  pep- 
tides.  This observation was not correlated with the size  of 
the tumor but rather with the clinical response to treatment 
with DC pulsed with the relevant tunmr peptides. Multiple 
vaccinations of antigen resulted in the progressive develop- 
ment of a Th2-associated response in addition to the Thl- 
associated immune  response elicited  during antigen  prim- 
ing.  Indeed,  the  11Bll  neutralizing anti-mIL-4 Abs were 
not able to significantly block the initiation of a DC pep- 
tide-induced  antitumor  immune  response  when  injected 
by day 4. The potential immunologic role of a late humoral 
response  cannot  be  ruled  out,  however,  since  the  11Bll 
reagent eventually significantly inhibited the DC-MCA205- 
mediated antitumor immune response by day 16. 
The  antitumor  therapeutic  efficacy  of peptide-pulsed 
DC was comparable, regardless of the tumor model and the 
mouse  strain  examined  (C57BL/6  [H-2  b]  or  BALB/c 
[H-2d]),  and  stresses  the  importance  of both  CD4 +  and 
CD8 + T  cells in the immunity induced by DC pulsed with 
class I-eluted tumor peptides. Mechanistically, we propose 
that BM-DC pulsed with tumor peptides migrate to lymph 
nodes and secrete or induce the secretion of IL-12, thereby 
driving  a  CD4 +  Thl-associated  inn-nune  response.  Such 
responses lead to the generation of IFN-y and TNF-c~, as 
well as,  presumably,  GM-CSF,  IL-3, and other cytokines 
released by activated Th cells,  which in  turn  may activate 
other APC in a positive feedback paracrine loop (upregula- 
tion of IL-12 and CD80/CD86  after CD40-gp39 ligation 
[46]).  DC  may present  class  I-eluted peptides  directly  to 
CD8 + T  cells,  which may also be activated after help pro- 
vided  by  the  DC-primed  CD4 +  T  cells.  An  enhanced 
CD8 +,  and to a lesser extent,  CD4 +,  T  cell infiltrate was 
reproducibly found in the peritumoral area as well as inside 
the  tunmr lesion  in animals treated with  DC pulsed with 
tumor peptides. 
Of note, whereas in vivo antibody neutralization studies 
clearly support the  requirement of IL-12 in  the  effective- 
ness  of DC-tumor  peptide-based  therapy,  no  additional 
statistically  significant  advantage  was  observed  with  sys- 
tenfic  coadministration  of  rlL-12,  suggesting  that  DC- 
based  therapies  elicit  sufficient  IL-12  for  clinical  impact. 
Alternatively, the dose of systemic rIL-12 that we used may 
be inappropriate for the observation of any additional ther- 
apeutic benefit, a hypothesis that we are currently evaluat- 
ing.  Nognchi et al.  (47)  studied  the influence of IL-12 on 
p53  peptide  vaccination  against  established  meth  A  sar- 
coma.  They  could  successfully  treat  mice  bearing  estab- 
lished  day  7  tumors  by immunizing  with  a  specific  syn- 
thetic  tumor peptide  plus  adjuvant only when  IL-12 was 
coadministered at very low doses (4 ng/mouse/wk) allow- 
ing  for  induction  of a  specific  CTL  response.  At  higher 
doses,  IL-12 suppressed  the  generation  of specific antitu- 
mor CTL. Interestingly, in our models, while not reflected 
in  enhanced  therapeutic  efficacy in  situ,  an  enhanced  tu- 
mor-specific CTL  response  could  be  elicited  (Fig.  3  A), 
and  the  immunity  transferred  to  naive  animals was  more 
potent when lymphocytes were derived from mice immu- 
nized  with  DC-MCA205  +  IL-12  compared with  DC- 
MCA205  alone.  Thus,  systemic  administration  of IL-12 
appears to positively influence the quality or nature of the 
resultant cellular immune response.  Notably, IL-12 (at the 
dose  used)  alone  is  an  efficient  antitumor  agent  in  mice 
bearing early day 4  MCA205  (Fig.  2 A), whereas in later 
day 8 tumor models, it has very little effect unless coadmin- 
istered with DC-MCA205  (Fig. 2 B). 
In summary, 5  ￿  10  s DC pulsed with acid-eluted tumor 
peptides significantly impair established tumor growth. The 
number of DC and the dose of peptides required for opti- 
mal therapeutic  index remain to  be defined.  It is possible 
that  the  immunogenicity  of peptide-pulsed  DC  may  be 
further  augmented by ex vivo culture  of DC  with  cyto- 
kines  in addition  to  IL-4  +  GM-CSF  or upon  the  engi- 
neering of cytokine genes into autologous DC, resulting in 
the paracrine delivery of cytokines at the site of DC-T-B 
cell clusters in lymphoid tissues.  Systenfic administration of 
cytokines such as IL-2 may also  allow for further dissemi- 
nation  and expansion of tumor-specific T  cells  elicited by 
these DC vaccines. 
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